AVADEL PHARMACEUTICALS (AVDL)

IE00BDGMC594 - Common Stock

14.86  -0.19 (-1.26%)

After market: 14.86 0 (0%)

Fundamental Rating

4

Taking everything into account, AVDL scores 4 out of 10 in our fundamental rating. AVDL was compared to 193 industry peers in the Pharmaceuticals industry. While AVDL seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, AVDL is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

AVDL had negative earnings in the past year.
AVDL had a negative operating cash flow in the past year.
In the past 5 years AVDL reported 4 times negative net income.
In the past 5 years AVDL always reported negative operating cash flow.

1.2 Ratios

AVDL has a Return On Assets of -67.43%. This is in the lower half of the industry: AVDL underperforms 72.40% of its industry peers.
AVDL has a Return On Equity of -151.13%. This is in the lower half of the industry: AVDL underperforms 67.71% of its industry peers.
Industry RankSector Rank
ROA -67.43%
ROE -151.13%
ROIC N/A
ROA(3y)-77.37%
ROA(5y)-50.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

AVDL's Gross Margin of 94.62% is amongst the best of the industry. AVDL outperforms 96.88% of its industry peers.
In the last couple of years the Gross Margin of AVDL has grown nicely.
AVDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.29%
GM growth 5Y3.15%

More info and screens

6

2. Health

2.1 Basic Checks

AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AVDL has been increased compared to 1 year ago.
The number of shares outstanding for AVDL has been increased compared to 5 years ago.
AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 1.54, we must say that AVDL is in the distress zone and has some risk of bankruptcy.
AVDL has a Altman-Z score of 1.54. This is in the better half of the industry: AVDL outperforms 61.98% of its industry peers.
There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.54
ROIC/WACCN/A
WACC7.15%

2.3 Liquidity

AVDL has a Current Ratio of 2.82. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
AVDL's Current ratio of 2.82 is in line compared to the rest of the industry. AVDL outperforms 44.27% of its industry peers.
AVDL has a Quick Ratio of 2.52. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AVDL (2.52) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.82
Quick Ratio 2.52

More info and screens

5

3. Growth

3.1 Past

AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.71%, which is quite impressive.
Looking at the last year, AVDL shows a very strong growth in Revenue. The Revenue has grown by 6260.23%.
AVDL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.99% yearly.
EPS 1Y (TTM)45.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.13%
Revenue 1Y (TTM)6260.23%
Revenue growth 3Y7.78%
Revenue growth 5Y-22.99%
Sales Q2Q%2674.33%

3.2 Future

AVDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.72% yearly.
AVDL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 81.02% yearly.
EPS Next Y76.8%
EPS Next 2Y53.17%
EPS Next 3Y41.48%
EPS Next 5Y27.72%
Revenue Next Year548.18%
Revenue Next 2Y234.95%
Revenue Next 3Y146.42%
Revenue Next 5Y81.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AVDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 21.37 indicates a rather expensive valuation of AVDL.
AVDL's Price/Forward Earnings ratio is rather cheap when compared to the industry. AVDL is cheaper than 80.21% of the companies in the same industry.
AVDL is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.28, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 21.37

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVDL's earnings are expected to grow with 41.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.17%
EPS Next 3Y41.48%

More info and screens

0

5. Dividend

5.1 Amount

AVDL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (11/4/2024, 8:00:00 PM)

After market: 14.86 0 (0%)

14.86

-0.19 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.35B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 21.37
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.43%
ROE -151.13%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 94.62%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.82
Quick Ratio 2.52
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)45.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y76.8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6260.23%
Revenue growth 3Y7.78%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y